Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases.
Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in four clinical trials, with the most advanced already in Phase 3. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year.
Biosion has operations in the US, Australia, and China.
To learn more about Biosion visit www.biosion.com.
Company Details
- Employees
- 23
- Founded
- -
- Address
- Building D, 3-1 Zhongdan Unit, South Longshan Rd, Jiangbei New District, 5th Floor,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.biosion.com
- HQ
- Nanjing, Jiangsu
Biosion Questions
Biosion's website is https://www.biosion.com
Biosion's LinkedIn profile is https://www.linkedin.com/company/biosion
Biosion has
23 employees.
View email and phone details for 23
employees at Biosion.
Biosion's industry is
Biotechnology Research
Biosion's categories are Biotechnology Research
Biosion's founding year is 2017
